emerging agents, including ADCs, for HER2-negative metastatic breast cancer and their impact on current and future practice.
With insights from Prof. Giuseppe Curigliano, Prof. Hope Rugo and Prof. Peter Schmid.
Watch now: touchoncologyime.org/new-and-...
--------
This activity is funded by an independent medical education grant from Gilead Sciences, Inc. and is jointly provided by USF Health and touchIME.